Halle Berry on Women's HRT: What She Has Said About Menopause Medication

What Has Halle Berry Actually Said About HRT?

Halle Berry has spoken about hormone replacement therapy in multiple documented public forums, including her Re-Spin podcast, Instagram posts, and interviews with outlets such as Women's Health magazine. Her statements are not rumor or inference. She has described being placed on hormone therapy after experiencing chest pain and heart palpitations that her physician identified as perimenopause rather than cardiac disease.

She has specifically referenced pellet therapy, a delivery method in which compressed hormone pellets are inserted subcutaneously, typically into the upper buttock, and release hormones over three to six months. Berry has credited this approach with resolving symptoms that had significantly affected her daily functioning.

The "Heart Attack" Statement

In a 2023 Instagram post and subsequent media appearances, Berry described going to the emergency room convinced she was having a heart attack. Her physician determined the episode was driven by perimenopause. This is clinically plausible. Palpitations, chest discomfort, and anxiety are well-documented vasomotor symptoms of the menopause transition, and a 2021 review in the journal Menopause confirmed that cardiac symptom mimicry is among the most underrecognized presentations of perimenopause [1].

Her Advocacy Role

Berry has used her platform to argue that menopause is systematically under-discussed and undertreated in medicine. She supported the Let's Talk Menopause organization's congressional advocacy efforts and has described her own physician, Dr. Tara Allmen, as a key guide through her treatment decisions. That framing matters clinically: it positions her statements as patient-reported experience, not medical advice.

What Is Pellet Therapy, the Delivery Method She Described?

Pellet therapy involves subcutaneous implantation of crystalline hormone pellets, most commonly containing estradiol, testosterone, or both. A clinician makes a small incision, typically in the upper gluteal region, and inserts pellets roughly the size of a grain of rice. The pellets dissolve over 90 to 180 days.

FDA Status and Compounding Concerns

This is where clinical nuance becomes essential. Estradiol pellets are available in FDA-approved forms, but the overwhelming majority of pellets used in clinical practice in the United States are compounded by 503A or 503B pharmacies. The FDA does not individually approve compounded preparations. The agency has noted that compounded hormones, including pellets, lack the safety and efficacy data required for standard drug approval [2].

The 2022 Menopause Society (formerly NAMS) position statement on compounded hormone therapy states: "Compounded hormone therapy should not be considered equivalent to FDA-approved menopausal hormone therapy, and there are no data demonstrating superior efficacy or safety" [3].

Testosterone Pellets and the Supraphysiologic Risk

Berry has referenced testosterone as part of her pellet regimen. Testosterone therapy for women is a legitimate clinical tool, but pellet dosing carries documented risk of supraphysiologic levels. A study published in Maturitas (2014, N=150) found that 43% of women receiving testosterone pellets had serum testosterone levels exceeding the normal female reference range at follow-up [4]. Supraphysiologic testosterone in women may cause acne, clitoral enlargement, voice changes, and polycythemia.

The Endocrine Society's clinical practice guideline on androgen therapy in women (2014) recommends against testosterone therapy outside of a diagnosed disorder of sexual interest and arousal, citing insufficient long-term safety data [5]. Some clinicians do prescribe testosterone off-label for energy, libido, and mood in menopause, but the evidence base differs from that of estrogen therapy.

Is HRT Itself Evidence-Based for Perimenopausal Women?

Yes, for appropriately selected patients. Halle Berry's use of HRT, as she has described it, falls within the population that current guidelines identify as candidates for therapy.

The 2023 Menopause Society Position

The Menopause Society (formerly NAMS) 2023 position statement is the most authoritative U.S. Clinical guideline on this topic. It states: "For women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture" [6].

Berry has publicly identified herself as being in her early fifties during the period she began therapy, which places her squarely within the population the guideline addresses.

WHI Reanalysis and the Fear Legacy

Menopause HRT uptake dropped sharply after the Women's Health Initiative (WHI) 2002 publication reported increased breast cancer and cardiovascular risk. Subsequent reanalysis demonstrated that the WHI population was older (mean age 63) and further from menopause onset than the typical candidate, and that younger initiators showed a different risk profile. A landmark reanalysis published in the Journal of the American Medical Association (Manson et al., 2013, JAMA) found that women aged 50 to 59 who received conjugated equine estrogen alone showed a 23% lower all-cause mortality compared to placebo over 18 years of follow-up [7].

Berry's advocacy indirectly addresses this legacy. She has described physicians who initially dismissed her symptoms, which aligns with documented evidence that menopause symptoms are undertreated. A 2020 survey published in Menopause (N=1,858) found that 73% of women with moderate-to-severe vasomotor symptoms were not receiving any pharmacologic treatment [8].

What Symptoms Did She Describe, and Are They Typical?

Berry described palpitations, anxiety, and what she called "feeling like I was losing my mind" during perimenopause. These are textbook vasomotor and neuropsychiatric symptoms of the menopause transition.

Vasomotor Symptoms

Hot flashes and night sweats affect an estimated 75% of women during perimenopause and menopause, per the North American Menopause Society [6]. Palpitations, which Berry described specifically, occur in a meaningful subset. A 2016 cross-sectional study in Climacteric (N=695) found that 47% of perimenopausal women reported heart palpitations as a bothersome symptom [9].

Cognitive and Mood Symptoms

The cognitive and mood complaints Berry described have biological grounding. Estrogen modulates serotonin and dopamine receptor expression in the prefrontal cortex. A 2021 study in Neuropsychopharmacology found that estradiol decline during perimenopause was associated with increased depressive symptom scores independent of sleep disruption [10]. Symptom onset is often abrupt and disorienting, which may explain why Berry initially sought emergency cardiac care.

The Misdiagnosis Pattern

Her experience reflects a documented clinical problem. Perimenopausal symptoms are frequently attributed to anxiety disorders, cardiac conditions, or thyroid disease before menopause is considered. The British Menopause Society's 2023 guidelines note that delays in menopause diagnosis of two or more years are common in primary care, contributing to avoidable symptom burden [11].

How Do the Treatments She Described Compare to Standard-of-Care Options?

Berry's described regimen (pellet-delivered estradiol and testosterone) sits outside the first-line recommendations in most major guidelines but is not categorically outside accepted clinical practice.

First-Line HRT Delivery Options (Guideline-Supported)

The Menopause Society and the Endocrine Society both favor transdermal estradiol as a preferred systemic delivery route because it avoids first-pass hepatic metabolism, which is associated with lower thromboembolism risk compared to oral conjugated equine estrogen. Standard options include:

• Transdermal estradiol patches (e.g., Climara, Vivelle-Dot) at 0.025 to 0.1 mg/day
• Estradiol gel (e.g., EstroGel) applied daily
• Oral estradiol at 0.5 to 2 mg/day
• Vaginal estradiol for genitourinary symptoms specifically

A 2019 BMJ study (N=900,000+) found that transdermal estradiol was not associated with increased venous thromboembolism risk, while oral estradiol carried a relative risk of approximately 1.58 compared to non-use [12].

Where Pellets Fit

Pellets provide continuous hormone release without daily adherence. That is a real benefit for some patients. The clinical concern is dose precision. Unlike a patch, which delivers a labeled amount per 24 hours, pellet output varies by pellet size, vascularity of the insertion site, and individual metabolism. The FDA has not cleared any compounded pellet for bioequivalence to a specific labeled dose. Clinicians using pellets should monitor serum hormone levels at four to six weeks post-insertion and adjust subsequent doses accordingly.

Testosterone for Women

No testosterone product is currently FDA-approved for women in the United States. Clinicians who prescribe testosterone for women do so off-label, typically using compounded creams, gels, or pellets at doses roughly one-tenth of those used in men. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 position statement supports testosterone therapy for hypoactive sexual desire disorder in postmenopausal women at physiologic doses, with monitoring [13].

What Does Her Advocacy Mean for Clinical Practice?

Public figures discussing hormone therapy can shift patient behavior at scale. When Berry posted about her perimenopause experience in 2023, search interest in "menopause HRT" spiked visibly on Google Trends within days. That kind of visibility has measurable effects.

Patient Conversations Triggered by Celebrity Disclosure

The clinical value is in the questions patients bring to appointments. A patient who arrives saying "I heard Halle Berry talks about pellet therapy, what is that?" gives a clinician an opening to discuss the full menu of options, compare evidence quality across delivery methods, and address WHI-era fears that still suppress appropriate prescribing. That conversation is productive regardless of whether pellets are ultimately the right choice for that patient.

What Clinicians Should Know About Her Statements

Berry's accounts are patient-reported experience. She has not claimed clinical expertise and, in most interviews, names her physician as the decision-maker. Clinicians can engage with her story without endorsing or refuting pellets categorically. The evidence supports HRT for her described symptom profile and demographic. The evidence is more mixed on compounded pellets as a delivery vehicle specifically.

A 2023 editorial in Menopause noted that celebrity menopause advocacy has contributed to a measurable increase in women initiating HRT discussions with their primary care physicians, an outcome the editorial characterized as broadly positive given rates of undertreatment [14].

Clinical Takeaway for Women Considering HRT

Women who identify with Berry's described experience, including cardiac-mimicking symptoms, cognitive fog, and mood disruption in their late forties or early fifties, should request a thorough menopause evaluation that includes FSH, estradiol, and thyroid function panels to confirm the menopause transition is driving symptoms.

For confirmed vasomotor symptoms in healthy women under 60 or within 10 years of menopause onset, transdermal estradiol with appropriate progestogen (in women with a uterus) represents the evidence-based first-line approach per the 2023 Menopause Society position statement [6]. Pellet therapy may be discussed as an option but requires informed consent about the compounded status of most preparations and the documented risk of supraphysiologic hormone levels requiring monitoring.